Advertisement

Durable Complete Responses After Discontinuation of Pembrolizumab in Metastatic Melanoma


Advertisement
Get Permission

As reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, and colleagues, a high proportion of patients with metastatic melanoma achieving a complete response on pembrolizumab (Keytruda) in the phase Ib KEYNOTE-001 trial maintained their complete response for prolonged durations after treatment discontinuation.1 

The current analysis included 105 patients (16.0%) who achieved a complete response among the 655 patients with ipilimumab (Yervoy)-naive or -treated advanced/metastatic melanoma who received 1 of 3 pembrolizumab regimens (2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks) in the KEYNOTE-001 trial. Eligible patients who received pembrolizumab for ≥ 6 months and at least two doses beyond a confirmed complete response could discontinue therapy. 

In the trial, response was centrally assessed every 12 weeks using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. For the current analysis, a complete response was defined on investigator assessment using immune-related response criteria. 

Prolonged Complete Responses

At data cutoff, with a median follow-up of 43 months, 92 of the 105 patients (87.6%) were still in complete response, with a median follow-up of 30 months from the first complete response; median duration of treatment in these patients was 24 months (range = 1–53 months). A total of 14 patients (13.3%) continued to receive treatment for a median of ≥ 40 months. 


Patients with metastatic melanoma can have durable complete remission after discontinuation of pembrolizumab, and the low incidence of relapse after median follow-up of approximately 2 years from discontinuation provides hope for a cure for some patients.
— Caroline Robert, MD, PhD and colleagues

Tweet this quote

Treatment was discontinued in 91 patients (86.7%), including 67 (63.8%) who were followed by observation without additional anticancer therapy. Among these 67 patients, the median time to overall response was 3 months (range = 0.5–11 months), the median time to complete response was 13 months (range = 3–36 months), the median duration of treatment was 23 months (range = 8–44 months), and the median duration of treatment after complete response was 7 months (range = 0.5–41 months).

As of data cutoff, only 7 of 105 patients with a complete response had confirmed progressive disease—2 while receiving initial pembrolizumab treatment, 4 after stopping pembrolizumab and proceeding to observation, and 1 who was reported as still receiving pembrolizumab; all 7 remained alive. Among all 105 patients who had a complete response, the estimated 24-month disease-free survival rate from the time of complete response was 90.9% (95% confidence interval [CI] = 82.5%–95.4%). 

Among the 67 patients who discontinued pembrolizumab after complete response for observation, the estimated 24-month disease-free survival from treatment discontinuation was 89.9%. Among all 89 patients who discontinued pembrolizumab after complete response for reasons other than progressive disease, the estimated 24-month disease-free survival from treatment discontinuation was 85.8%.

Potential Factors in Response

On univariate analysis among 459 patients with baseline data on tumor programmed cell death ligand 1 (PD-L1) status and tumor size, complete response was seen in 42.7% of those with smaller (1–5 cm) PD-L1–positive tumors (≥ 1% staining in tumor cells and mononuclear inflammatory cells). Patients with larger tumors (> 5 cm) had a lower complete response rate (< 10%), except for those with tumors measuring 5 to 10 cm and positive PD-L1 expression, who had a complete response rate of 20.5%; this rate was similar to the rate of 20.7% among those with smaller tumors (1–5 cm) who were PD-L1–negative. 

KEYNOTE-001 SUBANALYSIS

  • Among all 105 patients who had complete response, the estimated 24-month disease-free survival rate from the time of complete response was 90.9%.
  • Among 67 patients who discontinued pembrolizumab after complete response for observation, the estimated 24-month disease-free survival from treatment discontinuation was 89.9%.

The investigators concluded: “Patients with metastatic melanoma can have durable complete remission after discontinuation of pembrolizumab, and the low incidence of relapse after median follow-up of approximately 2 years from discontinuation provides hope for a cure for some patients. The mechanisms underlying durable complete response require further investigation.” ■

DISCLOSURE: The study was supported by Merck & Co. For full disclosures of the study authors, visit jco.ascopubs.org

REFERENCE

1. Robert C, Ribas A, Hamid O, et al: Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. December 28, 2017 (early release online).


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.